An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

BACKGROUND: BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has demonstrated antitumor activity in patients with BRAF V600E (Val600Glu)–mutant NSCLC. Dual MAPK pathway inhibition with BRAF and ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Planchard, David, Besse, Benjamin, Groen, Harry J M, Souquet, Pierre-Jean, Quoix, Elisabeth, Baik, Christina S, Barlesi, Fabrice, Kim, Tae Min, Mazieres, Julien, Novello, Silvia, Rigas, James R, Upalawanna, Allison, D’Amelio, Anthony M, Zhang, Pingkuan, Mookerjee, Bijoyesh, Johnson, Bruce E
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4993103/
https://ncbi.nlm.nih.gov/pubmed/27283860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30146-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados